Japan did not fix antibiotic resistance by inventing a new drug. It fixed antibiotic behavior by paying clinics when pediatricians choose not to prescribe.

The details matter, because the policy is aimed at one of the biggest sources of problematic use: Japanese pediatric outpatient clinics. According to Dr. Yusuke Okubo, chief of clinical epidemiology and health services research at the National Center for Child Health and Development in Tokyo, “90% of prescriptions are [from] outpatient clinics, not hospitals.” Those outpatient visits were where antibiotics were too often used for kids with conditions nine times out of 10 caused by viruses, like upper respiratory tract infections, and for other illnesses where antibiotics are usually unnecessary, like gastroenteritis. In other words, the program attacked the supply chain of resistance at the exact point where prescriptions were most likely to be mismatched to the underlying cause.

Japan’s incentive is simple in concept and serious in incentives. The government’s idea was: each time a pediatrician chose not to prescribe an antibiotic for those cases, the clinic earned a small financial reward. Each tip was about $5 per claim at today’s exchange rate, small enough to feel like a nudge, but large enough to reshape income at the clinic level. Okubo estimates Japanese pediatricians earn roughly $90,000 to $100,000 a year. A stream of thousands of extra dollars annually for clinics is not pocket change in a fee-sensitive practice environment, and it creates real momentum for changing day-to-day prescribing habits.

That matters because antibiotic resistance is not a slow, abstract problem. It is evolutionary pressure with consequences you can measure. With bacteria, a portion die when exposed to antibiotics, and a surviving portion carries traits encoded in “resistance genes.” Those genes can spread to the next generation through bacterial multiplication, and they can also be physically passed to nearby bacteria, plus acquired through random DNA mutations. All antibiotics carry some risk of resistance development, but broad-spectrum antibiotics carry more because they pressure a wider variety of bacteria. The source’s cross-country comparison in 2015 found Japan ranked dead last in the appropriateness of antibiotic choices for kids under 5. Specifically, Japanese doctors prescribed antibiotics with the lowest risk of resistance only 35% of the time.

The second-order risk is that the most “helpful-sounding” behavior in the moment can be the most harmful over time. Treating nonbacterial infections with antibiotics exposes bacteria unnecessarily, giving resistance the chance to evolve and spread. The program is also targeted where overuse had been documented. National insurance data sampled from 2005 showed 60% of patients in Japan with nonbacterial upper respiratory tract infections were prescribed antibiotics, mostly broad-spectrum ones such as third-generation cephalosporins, macrolides, and quinolones, and most of those prescriptions came from clinics. Globally, resistant bacterial infections caused 1.14 million deaths worldwide in 2021 and contributed to another 3.57 million deaths, and the source notes those numbers could climb dramatically by 2050 without swift action. In Japan, resistance is not just a theory. Resistant germs contribute to thousands of deaths each year, and older adults are especially affected, with people over 65 making up about 30% of Japan’s population.

But Japan did not rely on one program. It also embedded the effort in a broader regulatory and public-health push. In 2016, Japan released its first National Action Plan on Antimicrobial Resistance, aligned with a World Health Organization plan designed to raise awareness of AMR and optimize antimicrobial use among member states. Two big targets were to slash overall antibiotic use by 33% and broad-spectrum antibiotic use by 50% by 2020. The country came very close to hitting those deadlines, which is notable because changing prescribing patterns at scale is hard even when clinicians agree with the goal. The tipping program was one of a “slew of initiatives” introduced to improve AMR awareness and antibiotic use, including posters featuring the anime character Amuro Ray in an awareness campaign whose first name is similar to “AMR.”

For executives and boards, the strategic takeaway is that behavior-change policy can act like a product launch for stewardship. The incentive did not try to eliminate antibiotics. It tried to reduce unnecessary prescriptions, particularly broad-spectrum use, and it did so by aligning clinician incentives with resistance reduction. The source also flags that Japan historically overused antibiotics, and it describes resistance risks in children, including the possibility that resistant bacteria can pass from mothers to newborns at birth and cause serious complications like sepsis. It also notes outbreaks of Mycoplasma pneumoniae resistant to antibiotics, demonstrating that resistance is showing up in pathogens that frequently infect kids.

So could this work in the United States? The source frames it as a “nationwide experiment” with outpatient pediatrics as the focal point. In the U.S., outpatient practices account for a similar proportion of antibiotic prescriptions to Japan, which means the same leverage point exists. If you are a healthcare leader deciding how to tackle AMR risk, Japan’s approach suggests you may not need a single blockbuster intervention. You may need a repeatable mechanism that turns appropriate prescribing into a default choice, not a heroic effort. The stakes are the same everywhere: as alternatives to antibiotics lag and resistance rises, the cost of doing nothing shows up as preventable deaths, longer illness, and pressure on the remaining effective treatments.